BioportTriComboUK patient and professional information

Evidence

The evidence for Bioport TriCombo.

The published study on the TriCombo formulation and the manufacturer’s own documents, with direct links to each.

Product informationResources
A printed journal article open on a desk, showing graphs, a data table and a figure of a knee joint

Published study

The published study: joint-fluid rheology after injection.

Bioport TriCombo contains N-acetylglucosamine (NAG), chondroitin sulfate, a glycosaminoglycan (GAG), and hyaluronic acid, the lubricating component.2

A single-centre observational study of 52 patients with Kellgren-Lawrence grade 2 knee osteoarthritis followed a single 3 ml intra-articular injection of Kombihylan (3 MDa hyaluronate with chondroitin sodium sulfate and N-acetylglucosamine, each 30 mg/ml), given with or without a two-week multimodal physiotherapy programme, with synovial-fluid rheometry at six weeks. The group that combined the injection with physiotherapy showed higher shear viscosity and more consistent viscoelastic values, which the authors attribute to a synergistic effect. Bioport names Kombihylan as the active principles of TriCombo.1,2

Journal clinical

Iordan DA, 2025

Single-centre observational study, two groups · Knee · n = 52 · Follow-up: 6 weeks

Fifty-two adults with Kellgren-Lawrence grade 2 knee osteoarthritis received a single 3 ml intra-articular injection of Kombihylan, a viscoelastic solution of uncrosslinked 3 MDa hyaluronic acid with chondroitin sodium sulfate (30 mg/ml) and N-acetyl D-glucosamine (30 mg/ml). Thirty-seven also had ten physiotherapy sessions over two weeks; 15 had the injection alone. Synovial fluid sampled after injection and at six weeks showed higher shear viscosity and more consistent viscoelastic values in the group that combined the injection with physiotherapy. Bioport names Kombihylan as the active principles of TriCombo.1

View DOI
Published references for TriCombo, by study.
Author, yearDesignJointnFollow-upSummarySource
Iordan DA, 2025Single-centre observational study, two groupsKnee526 weeksFifty-two adults with Kellgren-Lawrence grade 2 knee osteoarthritis received a single 3 ml intra-articular injection of Kombihylan, a viscoelastic solution of uncrosslinked 3 MDa hyaluronic acid with chondroitin sodium sulfate (30 mg/ml) and N-acetyl D-glucosamine (30 mg/ml). Thirty-seven also had ten physiotherapy sessions over two weeks; 15 had the injection alone. Synovial fluid sampled after injection and at six weeks showed higher shear viscosity and more consistent viscoelastic values in the group that combined the injection with physiotherapy. Bioport names Kombihylan as the active principles of TriCombo.View DOI

Manufacturer documents

The brochure and the product page.

Composition, rheological values, indication and schedule on this site are transcribed from the manufacturer’s brochure.2

  • Cover of Bioport TriCombo product brochureBrochure

    Bioport TriCombo product brochure

    8 pages

    The manufacturer’s eight-page brochure: composition, concentration, rheological values, presentation, indication, the three ingredients and the six-month treatment schedule. Hosted here with the manufacturer’s contact block removed from the back page; authorship and copyright are unchanged.

    Open PDF
  • Cover of Bioport TriCombo product pageManufacturer product page

    Bioport TriCombo product page

    The manufacturer’s product page for TriCombo on bioport.fi.

    Visit manufacturer page

Safety

What the manufacturer states.

The manufacturer states that the absence of chemical or irradiation cross-linking decreases the chance of post-administration adverse reactions, listing pain at the injection site, local skin reactions, pseudoseptic reactions, septic arthritis, and local joint pain and swelling. Contraindications, warnings and precautions are governed by the instructions for use.2,3

References

  1. 1.Iordan DA, Coman MG, Hrisca-Eva OD, Stavrică-George A, Gherghin AC, Onu I. Enhanced Synovial Fluid Rheology in Moderate Knee Osteoarthritis Through Combined Intra-Articular Hyaluronic Acid and Multimodal Physiotherapy: A Monocentric Observational Study. Journal of Clinical Medicine, 14(17):6051, 2025. View DOI
  2. 2.Nikovari Bio Tech Oy. Bioport TriCombo product brochure. Manufacturer document, 8 pages, 2025. View source
  3. 3.Nikovari Bio Tech Oy. Bioport TriCombo instructions for use. Supplied with each pack, 2025. View source

Product details, or UK supply.

Composition, rheology and schedule in full, or a supply enquiry for your clinic.

Product informationUK supply